Clinical Trial Update: Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating imatinib mesylate as adjuvant therapy for patients with primary gastrointestinal stromal tumor completely removed by surgery has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Gastrointestinal Stromal Tumor | Phase 3 | Status: COMPLETED